Savara (SVRA) Change in Accured Expenses (2010 - 2026)
Savara's (SVRA) quarterly Change in Accured Expenses came in at -$4.6 million in Q1 2026, down 47.24% year-on-year from -$8.8 million in Q1 2025, and down 227.09% on a QoQ basis from $3.6 million in Q4 2025.
Savara (SVRA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Change in Accured Expenses data on file, last reported at -$4.6 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 47.24% year-over-year to -$4.6 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 82.06% increase from a year earlier, with the FY2025 full-year figure at $4.8 million, up 14.4% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$4.6 million, down from $3.6 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for SVRA reached as high as $3.6 million in Q4 2025 and fell as low as -$4.6 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $505529.4 across 5 years, with a median of $1.2 million in 2025.
- Across the five-year window, Change in Accured Expenses jumped 6075.0% in 2023 and slumped 308.83% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $445000.0 in 2022, then surged by 230.34% to $1.5 million in 2023, then soared by 53.74% to $2.3 million in 2024, then soared by 61.37% to $3.6 million in 2025, then plunged by 227.09% to -$4.6 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.6 million in Q1 2026, $3.6 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Savara | 1.40 Bn | 1.40 Bn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.64 Mn |
| Mar 31, 2026 | -4.64 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -770,000.00 |
| Mar 31, 2024 | -770,000.00 |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |